Abstract

In the UK, a national HPV immunisation programme was implemented in 2008 for girls aged 12–13 years. In addition a catch-up programme was implemented for older girls up to 18 years of age from 2009 to 2011, with an uptake rate of 49.4%. Information about future uptake of cervical screening according to vaccination statistics is important in order to understand the impact of the vaccination programme and implications for a national cervical screening programme. We analysed data on a cohort of women who had been offered the HPV vaccine in the catch-up programme and were invited for cervical screening between 2010 and 2012 in Wales (n=30,882), in a record-linked database study, to describe the cervical screening uptake and clinical outcome according to HPV vaccination status.In our cohort, 48.5% (n=14,966) women had had HPV vaccination and 45.9% (n=14,164) women attended for cervical screening. Women who were unvaccinated were less likely to attend cervical screening (adjusted OR 0.58; 95% CI (0.55, 0.61)). Of those who attended for screening, 13.9% of vaccinated women had abnormal cytology reported compared to 16.7% of women who were unvaccinated. Women who lived in areas with high levels of social deprivation were less likely to be vaccinated (Quintile 5 OR 0.48 95% CI (0.45, 0.52)) or attend cervical screening (Quintile 5 OR 0.70; 95% CI (0.65, 0.75)) compared to those who lived in the least deprived areas.These data highlight the need for new strategies to address inequalities in cervical screening uptake and can inform further mathematical modelling work to clarify the impact of the HPV vaccination programme on future cervical cancer incidence.

Highlights

  • There are two commercially available Human Papillomavirus (HPV) vaccines licensed by the FDA for prevention of cervical cancer: Cervarix® (GlaxoSmithKline) and Gardasil® (Sanofi Pasteur MSD)

  • In this study we report the factors associated with HPV vaccination uptake, cervical screening uptake and clinical outcome according to HPV vaccination status for the first cohort of women who had been offered the HPV vaccine and were invited for cervical screening within a national populationbased cervical screening programme in Wales

  • Data were available for 30,882 women from the Cervical Screening Wales (CSW) and 24,351 women from the National Community Child Health Database (NCCHD) (Fig. 1). 14,966/30,882 (48.5%) women had HPV partial or full vaccination and 14,164/30,882 (45.9%) women had attended for cervical screening. 2427/30,882 (7.9%) women had HPV partial vaccination and attended for cervical screening and 5579/30,882 (18.1%) women had HPV full vaccination and attended for cervical screening

Read more

Summary

Introduction

There are two commercially available Human Papillomavirus (HPV) vaccines licensed by the FDA for prevention of cervical cancer: Cervarix® (GlaxoSmithKline) and Gardasil® (Sanofi Pasteur MSD). A two-year catch-up vaccine arm was added for older girls who potentially would still benefit from the immune response induced by the HPV vaccine. Such a comprehensive national vaccination programme is expected to change the epidemiology of cervical cancer in the UK population. If women who are unvaccinated choose not to attend for cervical screening, and have high risk of exposure to HPV, the impact of the vaccination programme will be less

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call